Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate how cone beam computed tomography (CBCT) affects the therapeutic planning of impacted maxillary canines.
Study Design: A total of 132 impacted canines from 89 pediatric patients were collected from 3 specialist clinics in Stockholm, Sweden. An interdisciplinary therapy planning team consisting of 5 dental specialists evaluated each case and chose their preferred treatment alternative, initially without and later with CBCT images, to decide whether CBCT was justified for therapy planning. Predefined variables measurable using only 2-dimensional (2D) assessments were analyzed using stepwise logistic regression analyses.
Results: The CBCT was considered indicated in 47% of the cases. Additional information from CBCT led to a treatment decision change in 9.8%. Significant 2D predictors for CBCT justification were horizontal canine angulation compared with vertical angulation (odds ratio [OR] = 10.9), extraction strategy involvement (OR = 6.7), and buccally positioned canines compared with palatal (OR = 5.3), central (OR = 25.0), and distal or uncertain positions (OR = 7.7).
Conclusions: The benefit-risk assessment of CBCT for impacted canines may be reinforced by performing and applying justification decisions for CBCT acquisition at the therapeutic thinking level. If preliminary treatment planning motivates further in-depth investigation of either root status or tooth location, a CBCT is indicated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oooo.2022.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Segmentectomies Made Easy series: robotic-assisted right S1 and S2 segmentectomy.
Multimed Man Cardiothorac Surg
September 2025
Department of Thoracic Surgery, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, UK
Three-dimensional (3D) guided robotic-assisted thoracic surgery is increasingly recognized as the pioneering approach for the most complex of pulmonary resections, offering high-definition 3D visualization, enhanced instrument augmentation and tremor-free tissue articulation. Compared with open thoracotomy, the robotic platform is associated with reduced peri-operative morbidity, shorter hospital admissions and faster patient recovery. However, sublobar resections such as segmentectomies remain anatomically and technically demanding, particularly in the context of resecting multiple segments, as showcased in this right S1 and S2 segmentectomy.
View Article and Find Full Text PDFSegmentectomies Made Easy series: robotic-assisted left S1 and S2 segmentectomy.
Multimed Man Cardiothorac Surg
September 2025
Department of Cardiothoracic Surgery, St George’s Hospital, St George's University Hospitals NHS Foundation Trust, London, UK
Three-dimensional (3D) guided robotic-assisted thoracic surgery is increasingly recognized as a leading technique for undertaking the most complex pulmonary resections, providing high-definition 3D visualization, advanced instrument control and tremor-free tissue handling. Compared with open thoracotomy, the robotic platform offers reduced peri-operative complications, shorter hospital stays and faster patient recovery. Nevertheless, sublobar resections, such as segmentectomies, remain both anatomically intricate and technically challenging, particularly when resecting multiple segments, as in this left S1 and S2 segmentectomy.
View Article and Find Full Text PDFDesign of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFAn Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease.
Adv Ther
September 2025
Sanofi, Gentilly, France.
Introduction: No head-to-head studies comparing the efficacy of avalglucosidase alfa (AVA) with cipaglucosidase alfa + miglustat (Cipa+mig) have been conducted in patients with late-onset Pompe disease (LOPD). Two indirect treatment comparisons (ITCs) were conducted to estimate the effects of AVA versus Cipa+mig.
Methods: ITCs were conducted using simulated treatment comparisons (STCs), adjusting for differences in prognostic factors and treatment effect modifiers.
Recurrence associated with 2-year visual acuity after subretinal tissue plasminogen activator for submacular hemorrhage in neovascular age-related macular degeneration.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan.
Purpose: To identify predictors of the 2-year best-corrected visual acuity (BCVA) after subretinal tissue plasminogen activator (tPA) injection for massive submacular hemorrhage (SMH) complicating neovascular age-related macular degeneration (nAMD).
Study Design: A prospective, observational study.
Methods: This study included consecutive eyes with massive SMH and nAMD that underwent vitrectomy with subretinal tPA injection and follow-up for 2 years.